Combined with CRISPR/Cas9 technology, Eyquem et al incorporated the AAV6 vector-delivered anti-CD19-CAR into the TRAC locus of T cells and achieved a CAR insertion rate of more than 40%, showing more potent efficacy in killing CD19+ leukemia cells than conventional retrovirally produced CAR T cell.94 This evidence concerns the gene CD19 and leukemia.